Alcobra Stock Rating Lowered by Vetr Inc. (ADHD)

It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults. To view Vetr’s full report ...



from Meta Search Alerts http://ift.tt/1MrBE7L

via IFTTT